Tofacitinib effect on clotting tests in ulcerative colitis
Treatments studied
Part of Digestive system, Heart & circulation clinical trials.
This study looks at how tofacitinib (and related medicines) may affect clotting and blood-platelet function, and whether this could relate to blood clot risk. It includes detailed blood and stool/colonoscopy-related testing in adults with ulcerative colitis and in some people without it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be over 18 years old (and pregnant or breastfeeding is not allowed).
- If you have ulcerative colitis, you must be diagnosed with it and be currently active on scope/colonoscopy soon before starting.
- You must not have had a prior blood clot (thromboembolic event) in your history.
- You must not take medicines that change blood clotting or platelet function (like blood thinners or antiplatelet drugs).
- If you’re eligible as a woman who can become pregnant, you must use highly reliable birth control (error rate under 1% per year) and avoid combined hormonal birth control and hormone replacement therapy.
- For the “in-treatment” part, you must be starting your first medicine in this class (either a JAK inhibitor like tofacitinib or an anti-TNF medicine) for ulcerative colitis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether taking tofacitinib alone works as well as taking tofacitinib with mesalamine for people with ulcerative colitis who are already in remission. It aims to see if one medication can be stopped without causing a flare-up.
This study follows people with moderately to severely active ulcerative colitis who are taking the medication tofacitinib (Xeljanz). It aims to track any safety concerns in a real-world setting, using information already collected in a European registry (UR-CARE).
This trial tests if combining two medicines, vedolizumab and tofacitinib, helps control moderate to severe ulcerative colitis. It may be an option if other treatments, like anti-TNF drugs, haven't worked well for you.
This study looks at how common ulcerative colitis treatments (anti-TNF medicines, vedolizumab, or tofacitinib) change the health of your blood vessels. It may help doctors better understand cardiovascular risk in people with ulcerative colitis.
This study tests a medication called upadacitinib for people with inflammatory bowel disease (ulcerative colitis or Crohn's). The goal is to see how well it works and if it's safe.
This trial tests if combining two medications, infliximab and tofacitinib, works better than standard treatment for adults hospitalized with a severe flare of ulcerative colitis. If you have not been on these drugs before and meet certain health criteria, you may be able to join.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.